Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Global Market Report 2024

The cell and gene therapy contract development and manufacturing organization (CDMO) market size has grown exponentially in recent years. It will grow from $4.24 billion in 2023 to $5.41 billion in 2024 at a compound annual growth rate (CAGR) of 27.7%. The growth in the historic period can be attributed to favorable regulatory frameworks, increased technological advancements, high prevalence of genetic disorders, increased investments, and an increased number of strategic partnerships.

The cell and gene therapy contract development and manufacturing organization (CDMO) market size is expected to see exponential growth in the next few years. It will grow to $14.52 billion in 2028 at a compound annual growth rate (CAGR) of 28%. The growth during the forecast period can be attributed to expanded therapeutic applications, regulatory changes, increased investment, technological advancements, and global collaboration. Key trends expected in this period include rising demand for personalized therapies, growth in automation and digitalization, expansion of manufacturing capacities, the emergence of novel delivery systems, and a greater focus on sustainability and environmental impact.

The increasing prevalence of cancer cases is expected to drive the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Cancer, characterized by uncontrolled growth and spread of abnormal cells, is becoming more common due to aging populations, lifestyle changes, environmental exposures, and improved detection methods. CDMOs play a crucial role in combating cancer by developing and manufacturing innovative, targeted treatments that improve efficacy and patient outcomes. For example, according to Macmillan Cancer Support, a UK-based charitable organization, the number of people living with cancer in the UK is projected to rise from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the increasing prevalence of cancer cases is fueling the growth of the cell and gene therapy CDMO market.

Major companies in the cell and gene therapy contract development and manufacturing organization (CDMO) market are concentrating on broadening their portfolio by integrating advanced solutions such as PluriMatrix technology to improve the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary system designed for large-scale production of cell-based products. This innovative technology enables 3D expansion of cells on an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For example, in January 2024, Pluri, a biotech company based in Israel, introduced PluriCDMO, a new business division providing cell therapy manufacturing services as a CDMO. This new division encompasses a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri's newly established division delivers end-to-end services ranging from early preclinical stages to late-stage clinical trials and commercialization, covering process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as outlined in a company announcement. It harnesses the company's state-of-the-art PluriMatrix technology to provide advanced cell therapy manufacturing services.

In November 2023, Ajinomoto Co. Inc., a Japan-based company specializing in food and biotechnology, purchased Forge Biologics for $620 million. This acquisition enhances Ajinomoto's worldwide expertise in adeno-associated virus (AAV) and plasmid gene therapy manufacturing, strengthening its current contract development and manufacturing services. Forge Biologics, based in the US, is a contract development and manufacturing organization (CDMO) for gene therapy and a clinical-stage therapeutics company.

Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc, Merck & Co. Inc., Thermo Fisher Scientific Inc, Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc, Lonza Group, Catalent Inc, Charles River Laboratories International Inc, Sartorius Stedim Biotech, Samsung Biologics Co Ltd, WuXi Biologics, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc, Cell and Gene Therapy Catapult, VGXI Inc, Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A cell and gene therapy contract development and manufacturing organization (CDMO) is a specialized company that supports the development, manufacturing, and commercialization of cell-based and gene therapy products. These organizations provide services tailored to the specific needs of companies developing advanced therapies, including biopharmaceutical companies, academic institutions, and government agencies. Cell and gene therapy CDMOs are crucial in speeding up the development and commercialization of advanced therapy products by offering specialized expertise, infrastructure, and services from early-stage development through to commercialization.

The primary product types offered by cell and gene therapy contract development and manufacturing organizations (CDMOs) include gene therapy, gene-modified cell therapy, and cell therapy. Gene therapy involves altering or manipulating the genes within a person's cells to treat or prevent disease. These therapies undergo various phases, including phase 1, phase 2, phase 3, and phase 4, and are developed for a range of indications such as oncology, infectious diseases, neurological disorders, rare diseases, and others.

The cell and gene therapy contract development and manufacturing organization (CDMO) market research report is one of a series of new reports that provides cell and gene therapy contract development and manufacturing organization (CDMO) market statistics, including cell and gene therapy contract development and manufacturing organization (CDMO) industry global market size, regional shares, competitors with a cell and gene therapy contract development and manufacturing organization (CDMO) market share, detailed cell and gene therapy contract development and manufacturing organization (CDMO) market segments, market trends, and opportunities, and any further data you may need to thrive in the cell and gene therapy contract development and manufacturing organization (CDMO) industry. This cell and gene therapy contract development and manufacturing organization (CDMO) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell and gene therapy contract development and manufacturing organization (CDMO) market includes revenues earned by contract development and manufacturing organizations providing services for the development, manufacturing, and testing of cell and gene therapy products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.